

GUIDANCE ON PREVENTION OF VIRAL HEPATITIS B AND C
AMONG PEOPLE WHO INJECT DRUGS

2012



World Health
Organization

**GUIDANCE ON PREVENTION OF VIRAL HEPATITIS B AND C
AMONG PEOPLE WHO INJECT DRUGS**

July 2012

WHO Library Cataloguing-in-Publication Data

Guidance on prevention of viral hepatitis B and C among people who inject drugs.

1.Hepatitis C – prevention and control. 2.Hepatitis B – prevention and control 3.Hepatitis C – transmission. 4.Hepatitis B – transmission. 5.Substance abuse, intravenous – complications. 6.Guideline. I.World Health Organization.

ISBN 978 92 4 150404 1

(NLM classification: WC 536)

© World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Layout: L'IV Com, Villars-sous-Yens, Switzerland.

Printed by the WHO Document Production Services, Geneva, Switzerland.

CONTENTS

FUNDING AND DECLARATIONS OF INTEREST	4
ABBREVIATIONS AND ACRONYMS	5
EXECUTIVE SUMMARY	6
1. INTRODUCTION	11
2. SCOPE AND OBJECTIVES	12
3. BACKGROUND	13
3.1 Viral hepatitis B and C and injecting drug use	13
4. METHODOLOGY	16
4.1 WHO guideline development process	16
4.2 Viral hepatitis guideline development process	16
5. GUIDING PRINCIPLES	18
5.1 Human rights	18
5.2 Access to health care	18
5.3 Access to justice	18
5.4 Acceptability of services	19
5.5 Health literacy	19
5.6 Integrated service provision	19
6. RECOMMENDATIONS	20
6.1 Hepatitis B Vaccination	20
6.2 Type of syringes	26
6.3 Psychosocial and peer interventions	29
7. EXISTING RECOMMENDATIONS	35
8. ADAPTING THESE GUIDELINES	37
9. OPERATIONAL AND IMPLEMENTATION ISSUES	38
9.1 Health systems	38
9.2 Prevention services	38
9.3 Community involvement	38
10. NEXT STEPS	39
REFERENCES	40
ANNEXES	
All annexes can be found on the internet at	
http://www.who.int/hiv/pub/guidelines/hepatitis_annex/en/	
Annex 1: PICO questions	
Annex 2: Outcome frameworks	
Annex 3: GRADE notation and language	
Annex 4: GRADE evidence profiles	
Annex 5: Risk benefit/decision tables	
Annex 6: Evidence summaries	
Annex 7: Search strategies	
Annex 8: Report of Values and Preferences Survey	
Annex 9: Summary of declarations of interest	

ACKNOWLEDGEMENTS

The following people, from a range of background and specialities, have contributed to the development of this guidance. WHO is thankful for their time and their support.

Academic / research

Burnet Institute, Australia – Louisa Degenhardt, Margaret Hellard and Paul Nelson; **Christian Medical College, India** – Priya Abraham; **Cochrane Drugs and Alcohol Group, Italy** – Laura Amato, Marina Davoli, Silvia Minozzi, Zuzana Mitrova and Simona Vecchi; **Hospital Carlos III, Spain** – Vicente Soriano; **London School of Hygiene and Tropical Medicine, United Kingdom** – Peter Vickerman; **State University of New York at Buffalo, USA** – Elie Akl; **Treichvile University Teaching Hospital, Côte d'Ivoire** – Serge Paul Eholie; **University of New South Wales, Australia** – Lisa Maher; **University of São Paulo, Brazil** – Evaldo Stanislaw.

National programme managers

AIDS and Clinical Immunology Research Centre, Georgia – Tengiz Tsertsvadze; **Chinese Centre for Disease Control and Prevention, China** – Zhang Fujie; **Chumakov Institute of Poliomyelitis and Viral Encephalitis, Russia** – Karen Kyuregyan and Mikhail Mikhailov; **Ministry of Health, Tanzania** – Ahmed Khatib.

Programme implementers

Alaska Native Medical Center – Brian J McMahon; **Centers for Disease Control and Prevention, USA** – Eyasu Teshale and Siobhán O'Connor; **Médecins sans Frontières, United Kingdom** – Philipp Du Cros; **President's Emergency Plan for AIDS Relief, USA** – Lara Stabinski; **United States Agency for International Development, USA** – Billy Pick.

Civil society and community representatives

Eurasian Harm Reduction Network, Lithuania – Dasha Ocheret; **Harm Reduction International** – Catherine Cook; **International Network of People who Use Drugs, Australia** – Jude Byrne and Matt Southwell; **Treatment Action Group, USA** – Tracy Swan; **World Hepatitis Alliance, Bangladesh** – Md. Humayun Kabir; **World Hepatitis Alliance, United Kingdom** – Charles Gore.

World Health Organization

Headquarters

Department of HIV/AIDS – Andrew Ball, Txema Garcia Calleja, Philippa Easterbrook, Rachel Heenan, Ying-Ru Lo, Constance Mackworth-Young, Michelle Rodolph, Mira Schneiders, Annette Verster, and Marco Vitoria; **Department of Pandemic and Epidemic Diseases**

– Silvie Briand, Hande Harmanci, Jördis Ott and Steven Wiersma; **Department of Mental Health and Substance Abuse** – Nicolas Clark; **Department of Essential Health Medicines and Health Products** – Anita Sands; **Department of Maternal, Newborn, Child and Adolescent Health** – Lulu Muhe.

WHO Regional Offices

EURO – Irina Eramova; **SEARO** – Vason Pinyowiwat; **WPRO/Viet Nam Country Office** – Fabio Mesquita.

Other multilateral organizations

The Global Fund to Fight AIDS, Tuberculosis and Malaria – Mauro Guarinieri; **Joint United Nations Programme on HIV/AIDS** – Alison Crocket and Karen Stanecki; **United Nations Office on Drugs and Crime** – Monica Ciupagea.

Peer reviewers

Erika Duffell and Anastasia Pharrell (European Centre for Disease Prevention and Control, Sweden), Azzi Momenghalibaf (Open Society Foundation, USA), Kimberly Page (University of California, San Francisco, USA) and Steffanie Strathdee (University of California, San Diego, USA).

Overall coordination

Annette Verster and Ying-Ru Lo of the Department of HIV/AIDS, WHO Headquarters.

This guideline was written by Nick Walsh (independent consultant) and Annette Verster of the Department of HIV/AIDS, WHO Headquarters, with support from Michelle Rodolph and Elie Akl. Editing was done by Jura Editorial Services and layout by L'IV Com Sàrl.

FUNDING AND DECLARATIONS OF INTEREST

The development of these guidelines received financial support from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC).

Declaration of interest forms were collected from every member of each Guidelines Working Group. Eight potential conflicts of interest were declared. The WHO Secretariat assessed these declared conflicts of interest and determined that they were not sufficient to preclude these eight participants from participating in the development of the guidelines.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28590

